Deciphera Pharmaceuticals, Inc.’s Qinlock (ripretinib) is stuck in the later lines of gastrointestinal stromal tumor (GIST) treatment for the foreseeable future following the failure of a Phase III trial to bring it into earlier lines, while the biotech itself looks set to enter a lull for a while in terms of pipeline catalysts.
The company announced topline results on 5 November from the 453-patient Phase III INTRIGUE study comparing Qinlock against Pfizer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?